Design of Clinical Trials for Gene Therapy in Muscular Dystrophy

  • Jorge Quiroz
  • Kathryn WagnerEmail author


Gene therapy clinical trials in muscular dystrophy have commenced using intramuscular administration and have recently advanced to systemic administration of vector. This chapter will evaluate some of the elements of the design of clinical trials in gene therapy for muscular dystrophy that may optimize the safety and efficacy outcomes. Subject selection must consider preexisting immunity and the therapeutic window. While a placebo-controlled design is optimal, it may not be feasible in a pediatric trial. Efficacy outcome measures include muscle histology, muscle MRI, and functional tests. Safety outcome measures have special considerations for those with muscular dystrophy. Finally, ethical considerations important in design of clinical trials of gene therapy in muscular dystrophy include the principles of therapeutic misconception and justice.


Gene therapy Clinical trials Muscular dystrophy Ethics 


  1. 1.
    Gaudet D, Stroes ES, Methot J, Brisson D, Tremblay K, Benelot Moens SJ, Iotti G, Rastelletti I, Ardigo D, Corzo D, Meyer C, Andersen M, Ruszniewski P, Deakin M, Bruno MJ (2016) Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum Gene Ther 28:1–10Google Scholar
  2. 2.
    Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D, Methot J, Petry H, Gaudet D (2014) Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 25:180–188CrossRefGoogle Scholar
  3. 3.
    Kay MA, Manno CS, Ragni M, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nature 24:257–261Google Scholar
  4. 4.
    Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DGB, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA, Glader B (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101(8):2963–2972. CrossRefPubMedGoogle Scholar
  5. 5.
    Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA (2012) Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119(13):3038–3041. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ, Walker CM (2010) Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med 363(15):1429–1437. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68(5):629–638. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Herson S, Hentati F, Rigolet A, Behin A, Romero NB, Leturcq F, Laforet P, Maisonobe T, Amouri R, Haddad H, Audit M, Montus M, Masurier J, Gjata B, Georger C, Cherai M, Carlier PG, Hogrel JY, Herson A, Allenbach Y, Lemoine FM, Klatzmann D, Sweeney HL, Mulligan RC, Eymard B, Caizergues D, Voit T, Benveniste O (2012) A phase 1 trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 135:483–492CrossRefGoogle Scholar
  9. 9.
    Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, Martin AD, Fuller DD, Cleaver BD, Clement N, Phillips D, Islam J, Dobjia N, Byrne BJ (2013) Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 24:630–640CrossRefGoogle Scholar
  10. 10.
    Smith BK, Martin AD, Lawson LA, Vernot V, Marcus J, Islam S, Shafi N, Corti M, Collins SW, Byrne BJ (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity. Exp Neurol 287:216–224CrossRefGoogle Scholar
  11. 11.
    Corti M, Cleaver B, Clement N, Conlon TJ, Faris K, Wang G, Benson J, Tarantal AF, Fuller D, Herzog RW, Byrne BJ (2015) Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev 26(3):185–193CrossRefGoogle Scholar
  12. 12.
    Calcedo R, Wilson JM (2013) Humoral immune response to AAV. Front Immunol 4:341CrossRefGoogle Scholar
  13. 13.
    Golebiowski D, Conlon TJ, Coleman KE, Hewitt MM, Morris CA, Schneider J (2017) Profile of circulating and neutralizing antibody titers towards AAV8 and AAV9 in cynomolgus macaques. In: American Society of Gene and Cell Therapy 20th annual meeting, Washington DCGoogle Scholar
  14. 14.
    Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, Batshaw ML, Wilson JM (2011) Adeno-associated virus antibody profiles in newborns, children and adolescents. Clin Vaccine Immunol 18(9):1586–1588CrossRefGoogle Scholar
  15. 15.
    Salas D, Kwikker K, Majowicz A, Zabeleta N, Petry H, Aseguinolaza GG, Ferriera V (2017) Successful repeated hepatic gene delivery in non-human primates achieved with AAV5 by use of immune adsorption. In: American Society of Gene and Cell Therapy 20th annual meeting, Washington, DCGoogle Scholar
  16. 16.
    Corti M, LIberati C, Smith B, Lason LA, Conlon TJ, Erger K, Islam S, Fuller D, Collins S, Byrne BJ (2017) Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev 28(4):208–218CrossRefGoogle Scholar
  17. 17.
    Avexis I (2017) United States Securities and Exchange Commission: Form 10-K, Annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934. Accessed 3 July 2017
  18. 18.
    Cuker A (2017) Reversing and monitoring of DOACs. In: Hemostasis and Thrombosis Research Society, Scotsdale, AZ, April 7, 2017Google Scholar
  19. 19.
    Therapeutics D (2016) Press release: dimension announces interim topline results from ongoing phase 1/2 clinical program for DTX101, dimension’s lead AAV product candidate in development for adult patients with moderate/severe to severe hemophilia B. Accessed 3 July 2017
  20. 20.
    FDA (2017) Guidance for industry: E10 choice of control group and related issues in clinical trials. Accessed 22 April 2017
  21. 21.
    FDA (2017) FDA briefing information for the May 18, 2017 joint meeting of the pediatric advisory committee and the pediatric ethics subcommittee. Accessed 7 June 2017
  22. 22.
    Leung DG (2016) Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review. J Neurol 264(7):1320–1333. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316(23):1429–1435CrossRefGoogle Scholar
  24. 24.
    Andersen G, Dahlqvist JR, Vissing CR, Heje K, Thomsen C, Vissing J (2017) MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J Neurol 264(3):438–447. CrossRefPubMedGoogle Scholar
  25. 25.
    Godi C, Ambrosi A, Nicastro F, Previtali SC, Santarosa C, Napolitano S, Iadanza A, Scarlato M, Natali Sora MG, Tettamanti A, Gerevini S, Cicalese MP, Sitzia C, Venturini M, Falini A, Gatti R, Ciceri F, Cossu G, Torrente Y, Politi LS (2016) Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy. Ann Clin Transl Neurol 3(8):607–622. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Willcocks RJ, Rooney WD, Tiplett WT, Forbes SC, Lott DJ, Senesac CR, Daniles MJ, Wang D-J, Harrington AT, Tennekoon GI, Russman BS, Finager EL, Byrne BJ, Finkel RS, Walter GA, Sweeney HL, Vandenborne K (2016) Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large Duchenne muscular dystrophy cohort. Ann Neurol 79:535–547CrossRefGoogle Scholar
  27. 27.
    Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, Eagle M, Mayhew A, de Sousa PL, Dewar L, Morrow JM, Sinclair CD, Thornton JS, Bushby K, Lochmuller H, Hanna MG, Hogrel JY, Carlier PG, Vissing J, Straub V (2013) Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 8(8):e70993CrossRefGoogle Scholar
  28. 28.
    Arpan I, Willcocks RJ, Forbes SC, Finkel RS, Donovan JL, Rooney WD, Tiplett WT, Senesac CR, Daniles MJ, Byrne BJ, Finager EL, Russman BS, Wang D-J, Tennekoon GI, Walter GA, Sweeney HL, Vandenborne K (2014) Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 83:974–980CrossRefGoogle Scholar
  29. 29.
    Eichinger K, Heatwole C, Heininger S, Stinson N, Matichak Stock C, Grosmann C, Wagner KR, Tawil R, Statland JM, FSHD Clinical Trials Research Network (2017) Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve 55(3):333–337. CrossRefPubMedGoogle Scholar
  30. 30.
    Fischer D, Hafner P, Rubino D, Schmid M, Neuhaus C, Jung H, Bieri O, Haas T, Gloor M, Fischmann A, Bonati U (2016) The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: a cross-sectional study. Neuromuscul Disord 26(7):414–422. CrossRefGoogle Scholar
  31. 31.
    McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, Glanzman AM, Group PG-DS, Spiegel R, Barth J, Elfring G, Reha A, Peltz SW (2013) The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48(3):357–368. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK (2015) A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 23(1):192–201. CrossRefPubMedGoogle Scholar
  33. 33.
    Han JJ, Kurillo G, Abresch RT, De Bie E, Nicorici A, Bajcsy R (2015) Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect. Muscle Nerve 52(3):344–355. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S, D’Amico A, Messina S, Battini R, Scutifero M, Petillo R, Frosini S, Scalise R, Vita G, Bruno C, Pedemonte M, Mongini T, Pegoraro E, Brustia F, Gardani A, Berardinelli A, Lanzillotta V, Viggiano E, Cavallaro F, Sframeli M, Bello L, Barp A, Bonfiglio S, Rolle E, Colia G, Catteruccia M, Palermo C, D’Angelo G, Pini A, Iotti E, Gorni K, Baranello G, Morandi L, Bertini E, Politano L, Sormani M, Mercuri E (2014) Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 24(3):201–206. CrossRefPubMedGoogle Scholar
  35. 35.
    Han JJ, Kurillo G, Abresch RT, de Bie E, Nicorici A, Bajcsy R (2015) Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by kinect. Muscle Nerve 51(2):168–175. CrossRefPubMedGoogle Scholar
  36. 36.
    Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group, Telethon Foundation DMD Italian Network (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79(2):257–271. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362(15):1396–1406. CrossRefPubMedGoogle Scholar
  38. 38.
    McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM, Group PG-DS, Spiegel R, Barth J, Elfring G, Reha A, Peltz S (2013) THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48(3):343–356. CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    US Department of Health and Human Services Food and Drug Administration, CfDEaR, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health (2009) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. BethesdaGoogle Scholar
  40. 40.
    Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, McDermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT (2016) Myotonic dystrophy health index: correlations with clinical tests and patient function. Muscle Nerve 53(2):183–190. CrossRefPubMedGoogle Scholar
  41. 41.
    Johnson NE, Quinn C, Eastwood E, Tawil R, Heatwole CR (2012) Patient-identified disease burden in facioscapulohumeral muscular dystrophy. Muscle Nerve 46(6):948–950. CrossRefGoogle Scholar
  42. 42.
    Klingels K, Mayhew AG, Mazzone ES, Duong T, Decostre V, Werlauff U, Vroom E, Mercuri E, Goemans NM, The Upper Limb Clinical Outcome Group (2017) Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. Dev Med Child Neurol 59(2):224–231. CrossRefPubMedGoogle Scholar
  43. 43.
    Binks M, Schomaker S, Marraffino S, Fitz L, Warner R, Johnson K, Aubrecht J (2016) Evaluation of glutamate dehydrogenase as a clinical biomarker of liver injury in patients with Duchenne muscular dystrophy. In: Muscular Dystrophy Association conference, Washington DCGoogle Scholar
  44. 44.
    Wilson JM (2010) Autoimmunity, recessive diseases and gene replacement therapy. Mol Ther 18(12):2045–2047CrossRefGoogle Scholar
  45. 45.
    Rumney P, Anderson JA, Ryan SE (2015) Ethics in pharmacologic research in the child with a disability. Pediatr Drugs 17:61–68CrossRefGoogle Scholar
  46. 46.
    Kimmelman J (2009) Ethics of cancer gene transfer clinical research. In: Walther S (ed) Methods in molecular biology, gene therapy of cancer, vol 542. Humana Press, New YorkGoogle Scholar
  47. 47.
    Unguru Y, Sill AM, Kamani N (2010) The experience of children enrolled in pediatric oncology research: implications for assent. Pediatrics 125(4):e876–e883CrossRefGoogle Scholar
  48. 48.
    Tilburt J, Ford JG, Howerton MW, Gary TL, Lai G, Bolen S, Balffi C, Wilson RF, Tanpitukpongse TP, Powe NR, Bass EB, Sugarman J (2007) Applying justice in clinical trials for diverse populations. Clin Trials 4:264–269CrossRefGoogle Scholar
  49. 49.
    Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJJ (1999) Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist 4:501–508PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Solid BiosciencesCambridgeUSA
  2. 2.Kennedy Krieger InstituteJohns Hopkins School of MedicineBaltimoreUSA
  3. 3.Department of NeurologyJohns Hopkins School of MedicineBaltimoreUSA
  4. 4.Department of NeuroscienceJohns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations